FG 3175
Alternative Names: FG-3175Latest Information Update: 11 Sep 2024
At a glance
- Originator FibroGen
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; CCR8 receptor antagonists; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 03 Jun 2024 FibroGen in collaboration with Regeneron Pharmaceuticals plans a clinical trial for Solid tumours (Monotherapy, Combination therapy)
- 03 Jun 2024 FibroGen enters into a research and development agreement with Regeneron Pharmaceuticals for FG 3175
- 26 Feb 2024 FibroGen expect to files an IND application in 2025